BioSpace News Archive

Medial EarlySign (earlysign.com), a pioneering company developing AI-based clinical predictive analytics, announced at the recent HIMSS Conference a new agreement with Roche, which will allow for EarlySign ColonFlag to be offered within the navify® Algorithm Suite from Roche Diagnostics.

Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced the appointment of Dr. Jack Antel to its Clinical Advisory Board (CAB).

ViaLase, Inc. today announced that it will present first-in-human clinical data and a technology overview during the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held May 5-8, 2023 in San Diego, California.

AllyGPO, a next-generation, physician-led group purchasing organization (GPO) dedicated exclusively to community specialty practices, today announced the appointment of Mike Cunningham, PharmD, to its Board of Directors.

I-Mab announced that it has filed its annual report on Form 20-F for the year ended December 31, 2022 with the U.S. Securities and Exchange Commission on May 1, 2023.

IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that its participation in the American Society of Breast Surgeons’ (ASBrS) 24th Annual Meeting.

Corbus Pharmaceuticals Holdings, Inc. today announced that an abstract highlighting pre-clinical data for CRB-601, its avβ8 blocking antibody, has been accepted for oral presentation in the main program of the New York Academy of Sciences’ 2023 Frontiers in Cancer Immunotherapy meeting, taking place in New York, NY May 2-4, 2023.

Akebia Therapeutics, Inc. today announced plans to release its financial results for the first quarter ended March 31, 2023 on Monday, May 8, 2023, prior to the open of financial markets.

Inspirna, Inc. announced today the appointment of Dr. Usman “Oz” Azam, M.D., as its new Chief Executive Officer.

Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA ® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED).